Release Date: 09-Jul-2025
The US market for orphan drugs has been growing spectacularly since 1983, when the Orphan Drug Act (ODA), a landmark policy aimed at encouraging therapy development for rare diseases, i.e., those that afflict fewer than 200,000 individuals in the US, was enacted. The law provided for major incentives like tax credits, waivers of user fees, and seven years of market exclusivity for drugs approved. These incentives clearly worked highly effectively to promote investment in this highly specialized area.
Download Report: https://www.kuickresearch.com/report-fda-orphan-drug-database
As of June 2025, the US Food and Drug Administration (FDA) had granted more than 7,300 orphan drug designations. These designations were for treatments against more than 1,000 rare diseases. Notably, this has translated to more than 1,300 approved orphan-designated products, of which over 800 original approvals were for nearly 400 unique rare diseases. This expanding pipeline reflects expanding scientific and commercial interest in therapy for rare diseases.
Today, over 500 active orphan drugs are being marketed in the US, treating a broad array of therapeutic categories. Oncology is the leading indication, with nearly 40% of orphan drug approvals and designations. This is followed by neurology and hematology, both of which demonstrate high levels of innovation and unmet clinical need. This growing pipeline demonstrates growing scientific and commercial interest in rare disease treatment. The US alone is estimated to represent more than 60% of global orphan drug sales, highlighting its position at the center of driving growth in this market.
One of the most recent additions to the US market is Imaavy (nipocalimab), developed and commercialized by Janssen Pharmaceuticals. FDA-approved in April 2025, Imaavy is used in the treatment of generalized myasthenia gravis (gMG) in adults and pediatric patients aged 12 years and older who are positive for anti-acetylcholine receptor or anti-MuSK antibodies. It is an effectorless IgG anti-FcRn fully human monoclonal antibody. The medicine gained its orphan drug designation in 2021 and is a huge leap forward for individuals with this rare autoimmune neuromuscular disorder.
The other recent approval in 2025 is penpulimab from Akeso. The FDA granted orphan drug designation to the drug in 2021 for the treatment of nasopharyngeal carcinoma, a rare head and neck cancer more prevalent among East Asian populations. The anti-PD-1 monoclonal antibody penpulimab was approved along with cisplatin or carboplatin and gemcitabine. This approval broadens the treatment options for a disease with few therapeutic choices and reflects the FDA's ongoing commitment to treating rare cancers.
The expansion of the orphan market is driven not only by regulatory incentives but also by the development in genomics, personalized medicine, and biologics. Such scientific advancements are enabling developers to understand the mechanisms of disease more effectively and attack them with increased precision. Small and large pharmaceutical companies, as well as small biotech companies, are also investing significant amounts in research on rare diseases, based on the potential of the market and the importance of the market to patients.
Looking ahead, the future of the US market for orphan drugs is bright. With more than 7,000 rare diseases impacting millions of Americans, most of which still have no approved treatments, there is ample room for expansion. Future approvals will be influenced by mounting innovation, more specialized treatments, and better diagnostic capabilities. Sustained cooperation between regulators, industry, and patient groups will be critical to ensuring that the next generation of orphan medicines brings significant benefits to whom they are most needed. US FDA Approved Orphan Drug Market us orphan drug market fda designated orphan drug market us orphan drug market size usa orphan drug market sales orphan drug sales in us orphan drug market in usa